 Englewood Cliffs, NJ, Feb. 23, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTCQB: SILO, a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinsons, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactives One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST. 